0001731122-21-001492.txt : 20210910 0001731122-21-001492.hdr.sgml : 20210910 20210910162525 ACCESSION NUMBER: 0001731122-21-001492 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20210910 ITEM INFORMATION: Other Events FILED AS OF DATE: 20210910 DATE AS OF CHANGE: 20210910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000837490 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043683628 STATE OF INCORPORATION: DE FISCAL YEAR END: 0615 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-23460 FILM NUMBER: 211247332 BUSINESS ADDRESS: STREET 1: 73-4460 QUEEN KA'AHUMANU HWY. STREET 2: SUITE 110 CITY: KAILUA-KONA STATE: HI ZIP: 96740 BUSINESS PHONE: 954-648-2013 MAIL ADDRESS: STREET 1: 73-4460 QUEEN KA'AHUMANU HWY. STREET 2: SUITE 110 CITY: KAILUA-KONA STATE: HI ZIP: 96740 FORMER COMPANY: FORMER CONFORMED NAME: AQUASEARCH INC DATE OF NAME CHANGE: 19920703 8-K 1 e3086_8-k.htm FORM 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) : September 10, 2021

 

 

MERA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   333-23460   04-3683628
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

8275 S. Eastern Ave. Suite 200, Las Vegas, NV 89123

(Address of principal executive offices) (Zip Code)

 

604-500-4157

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01Other Items

 

Mera Pharmaceuticals, Inc. financials attached.

 

Exhibits

 

99aBalance Sheet
99bProfit and Loss

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Mera Pharmaceuticals, Inc.
     
Dated: September 10, 2021 By:  
  Name: Benny Doro
  Title: Chief Executive Officer and President

 

 

 

 EX-99.A 2 e3086_ex99a.htm EXHIBIT 99A

 

 

EXHIBIT 99a

 

Mera Pharmaceuticals, Inc.

Balance Sheet

As of September 8, 2021

 

   Sep 8, 21
ASSETS   0.00 
LIABILITIES & EQUITY     
Liabilities     
Current Liabilities     
Accounts Payable     
Accounts Payable   38,649.08 
Total Accounts Payable   38,649.08 
Total Current Liabilities   38,649.08 
Total Liabilities   38,649.08 
Equity     
Preferred Stock - Series A   1.00 
Preferred Stock - Series B   1.00 
Common Stock   54,777.00 
Additional Paid-in Capital   7,968,873.00 
Treasury Stock   -2,025.00 
Retained Earnings   -8,052,317.00 
Net Income   -7,959.08 
Total Equity   -38,649.08 
TOTAL LIABILITIES & EQUITY   0.00 

 

 

 

 EX-99.B 3 e3086_ex99b.htm EXHIBIT 99B

 

 

EXHIBIT 99b

 

Mera Pharmaceuticals, Inc.

Profit & Loss

November 1, 2020 through September 8, 2021

 

   Nov 1, ‘20 - Sep 8, 21
Ordinary Income/Expense     
Expense     
Corporate Registration/Licensin   4,734.08 
Transfer Agent and Filing Fees   4,155.00 
Total Expense   8,889.08 
Net Ordinary Income   -8,889.08 
Net Income   -8,889.08